Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Venetoclax Combination Therapy for IDH-mutated AML

August 19th 2021

Key opinion leader in the management of acute myeloid leukemia, Harry Erba, MD PhD, builds a conversation on the use of venetoclax as a part of combination therapy in patients with IDH mutations.

Zandelisib/Zanubrutinib Produces Promising Safety, Efficacy in Relapsed/Refractory B-Cell Malignancies

August 18th 2021

Alexey V. Danilov, MD, discusses the safety and efficacy achieved with the novel combination comprised of zandelisib and zanubrutinib in patients with relapsed/refractory B-cell malignancies.

Approaches to Treatment for Relapsed/Refractory ALL

August 17th 2021

Ibrahim Aldoss, MD and James K. McCloskey, MD describe treatment modalities that can be utilized in treating a pediatric or AYA patient with relapsed / refractory ALL.

Approaches to Treatment After Failure to Achieve MRD Negativity

August 17th 2021

Insights on how to approach an acute lymphocytic leukemia patient who is MRD positive after induction therapy.

Case 1: Treatment Algorithm and Supportive Care Recommendations

August 16th 2021

Patricia Lugar, MD, MS, shares treatment algorithm and supportive care recommendations for a 75-year-old man with systemic mastocytosis.

Dr. Miller on the Characteristics of Clonal Hematopoiesis

August 16th 2021

Peter G. Miller, MD, PhD, discusses the characteristics of clonal hematopoiesis.

Case 1: Treatment and Management Considerations

August 16th 2021

The panel of experts in SM discuss the diagnosis and management of a 75-year-old man with systemic mastocytosis.

Frontline Targeted Therapy in CLL: Tolerability and Toxicity Management

August 16th 2021

A comprehensive breakdown of the tolerability of frontline targeted therapies used to manage chronic lymphocytic leukemia and toxicity management.

Optimizing the Frontline Management of High-Risk CLL

August 16th 2021

After determining the parameters of high-risk CLL, key opinion leaders clarify optimal frontline management strategies.

Optimal Approaches to Bridging Therapy in DLBCL

August 16th 2021

Greg Nowakowski, MD, explains optimal approaches to bridging therapy before CAR T cell therapy in DLBCL.

Evaluating CAR T Therapies in Lymphoma

August 16th 2021

A panel of experts explain the differences among the multiple trial designs, patient populations, and CAR T constructs used for treatment of non-Hodgkin lymphoma.

Making the Most of Therapeutic Options in Multiple Myeloma

August 13th 2021

Krina K. Patel, MD, MSc, discusses the use of CAR T-cell therapy in multiple myeloma, potential target antigens beyond BCMA, the rich research landscape, and the role of quadruplets and radiation therapy.

Updates in the Treatment of Waldenström Macroglobulinemia

August 13th 2021

This article discusses the current treatment landscape and therapeutic strategies for Waldenström macroglobulinemia, the role of Bruton tyrosine kinase inhibitor therapies in WM, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.

Duvelisib Induces Encouraging ORR in Relapsed/Refractory Peripheral T-Cell Lymphoma

August 13th 2021

Duvelisib monotherapy demonstrated encouraging efficacy for patients with relapsed/refractory peripheral T-cell lymphoma.

HMAs in High-Risk MDS

August 13th 2021

The panel of experts comment on the optimal timing of hypomethylating agents and transplant in patients with high-risk myelodysplastic syndrome.

Zandelisib Plus Rituximab Under Study in Indolent Non-Hodgkin Lymphoma

August 13th 2021

Zandelisib plus rituximab is being evaluated as a potentially chemotherapy-free treatment strategy vs standard chemoimmunotherapy in patients with indolent non-Hodgkin lymphoma in first relapse in the ongoing, phase 3 COASTAL trial.

Use of HMAs for the Treatment of MDS

August 13th 2021

The panel of experts highlight the risk factors and considerations for use of hypomethylating agents in patients with myelodysplastic syndrome versus acute myeloid leukemia.

Dr. Zeidner on Transformation to AML in Higher-Risk MDS

August 12th 2021

Joshua F. Zeidner, MD, discusses the risk of transformation to acute myeloid leukemia in higher-risk myelodysplastic syndromes.

Zanubrutinib Shows Encouraging Tolerability, Activity in BTK Inhibitor–Intolerant B-Cell Malignancies

August 12th 2021

Zanubrutinib demonstrated clinical activity and tolerability in previously treated patients with B-cell malignancies who were intolerant to therapy with ibrutinib and/or acalabrutinib, according to results of the phase 2 BGB-3111-215 trial.

Combination Approaches Targeting FLT3 and IDH Mutations

August 12th 2021

Expert hematologist-oncologists share insights into clinical trials studying how to best combine or sequence FLT3 and IDH inhibitors in patients with both mutations.